AGN Media thread, page-89

Dr Liz Dallimore on the exciting times ahead for Argenica Therapeutics as they fast track Phase 2

MAKING MONEY MATTER: Biotech companies have not been top of investors minds recently but I was excited to speak with Dr Liz Dallimore of Argenica Therapeutics (ASX:AGN) who are moving from Phase 1 to Phase 2 trials. Since we last spoke there has been a steady increase in the share price as they work on a drug to reduce brain damage after strokes as well as other brain injuries.

TIME STAMPS:

00:00 intro

02:00 Background to Argenica Therapeutics (asx:AGN) and what sets them apart

04:30 Phase 1 and Phase 2 trials and the outcomes from the trials

06:50 The competition

08:30 The recent placement and use of funds going forward

12:00 The importance of the FDA approval and the market in the USA

14:30 Timelines for the phase 2 trials and any challenges?

18:00 Progress with the FDA

21:00 Current valuation and milestones ahead and future partners

23:30 The other applications for the company going forward

26:30 Three reasons to sit up and take notice right now